Expressions of E-cadherin and vascular endothelial growth factor in gastrointestinal stromal tumors and their clinical significances_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LI Bo ¹ ,  JIANG Lixin ¹ , HU Jinchen ¹ , ZHANG Menglai ¹ , JIA Rongbao ¹ , YU Hualong ¹ , CAI Li ²

1. Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P. R. China;
2. Department of Pathology, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P. R. China;

Corresponding?author：

JIANG Lixin, Email: jianglixin1969@hotmail.com

Keywords：

gastrointestinal stromal tumor; E-cadherin; vascular endothelial growth factor; risk classification

DOI：

10.7507/1007-9424.201910069

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect expressions of E-cadherin (E-cad) and vascular endothelial growth factor (VEGF) in gastrointestinal stromal tumor (GIST) tissues and analyze their relationships with clinicopathologic features of patients with GIST.Methods Forty paraffin-embeded specimens of surgical resected GIST from January 2015 to March 2018 in the Pathology Department of Yuhuangding Hospital Affilicated to Qingdao University were retrieved. The expressions of E-cad and VEGF proteins were detected by the immunohistochemical method.Results The positive expression rates of E-cad and VEGF proteins in the GIST tissues were 10.0% (4/40) and 50.0% (20/40), respectively. The positive expression rates of E-cad and VEGF proteins were associated with the tumor diameter, mitotic counts, and risk classification (P<0.05). The positive expression rate of the E-cad was negatively related to that of the VEGF in the GIST tissues (r_s=–0.55, P=0.001).Conclusion From results of this study, VEGF and E-cad might be related with malignancy of GIST, which might be potential facators in predicting prognosis of GIST.

Citation： LI Bo, JIANG Lixin, HU Jinchen, ZHANG Menglai, JIA Rongbao, YU Hualong, CAI Li. Expressions of E-cadherin and vascular endothelial growth factor in gastrointestinal stromal tumors and their clinical significances. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(8): 970-974. doi: 10.7507/1007-9424.201910069 Copy

1.	中國臨床腫瘤學會胃腸間質瘤專家委員會. 中國胃腸間質瘤診斷治療共識(2017年版). 腫瘤綜合治療電子雜志, 2018, 4(1): 31-43.
2.	Huang H, Liu YX, Zhan ZL, et al. Different sites and prognoses of gastrointestinal stromal tumors of the stomach: report of 187 cases. World J Surg, 2010, 34(7): 1523-1533.
3.	Muranushi R, Hoshino K, Hagiwara K, et al. Hepatic pleomorphic leiomyosarcoma after surgery for gastric gastrointestinal stromal tumor: a case report. Surg Case Rep, 2019, 5(1): 62.
4.	Costache MI, Ioana M, Iordache S, et al. VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Rom J Intern Med, 2015, 53(3): 199-208.
5.	楊顯金, 陳佳慧, 杜江, 等. 胃腸道間質瘤的診治現狀與進展. 中國普外基礎與臨床雜志, 2014, 21(8): 1040-1045.
6.	Yang J, Gu Y, Huang X, et al. Prognostic impact of preoperative neutrophil-lymphocyte ratio for surgically resected gastrointestinal stromal tumors. Medicine (Baltimore), 2019, 98(16): e15319.
7.	Parab TM, DeRogatis MJ, Boaz AM, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol, 2019, 10(1): 144-154.
8.	岳欣, 胡均, 王家倉. 甲磺酸伊馬替尼治療手術無法切除的晚期胃腸間質瘤. 中國腫瘤臨床, 2016, 43(23): 1049-1052.
9.	Feng Y, Wang X, Wang Q. Expression of SATB1 and E-cad in tissues of patients with endometrial carcinoma and the relationship with clinicopathological features. Exp Ther Med, 2018, 15(5): 4339-4343.
10.	Villagrasa P, Díaz VM, Vi?as-Castells R, et al. Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene, 2012, 31(36): 4022-4033.
11.	金鑫, 李靖, 錢軍. ALDH1、CXCR4、E-cadherin在胃癌組織中的表達及與淋巴結轉移的關系. 南方醫科大學學報, 2016, 36(10): 1390-1395.
12.	楊學民, 李朝路, 李兆陽. ICAM-1、MMP-9及E-cadherin在結直腸癌中的表達及意義. 癌癥進展, 2018, 16(10): 1284-1287.
13.	K?vecsi A, Gurzu S, Szentirmay Z, et al. Paradoxical expression pattern of the epithelial mesenchymal transition-related biomarkers CD44, SLUG, N-cadherin and VSIG1/Glycoprotein A34 in gastrointestinal stromal tumors. World J Gastrointest Oncol, 2017, 9(11): 436-443.
14.	Lim SC, Jang IG, Kim YC, et al. The role of E-cadherin expression in non-small cell lung cancer. J Korean Med Sci, 2000, 15(5): 501-506.
15.	Kim NG, Koh E, Chen X, et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A, 2011, 108(29): 11930-11935.
16.	梁建芳, 鄭繪霞, 李寧, 等. 胃腸道間質瘤中P16基因甲基化和P16蛋白表達的臨床意義. 中華胃腸外科雜志, 2007, 10(4): 372-375.
17.	Ravegnini G, Nannini M, Zenesini C, et al. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, 20(1): 139-148.
18.	Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
19.	Hu F, Li H, Liu L, et al. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling. Mol Cancer, 2018, 17(1): 107.
20.	Banys-Paluchowski M, Witzel I, Aktas B, et al. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Sci Rep, 2019, 9(1): 2318.
21.	Skirnisdottir I, Seidal T, ?kerud H. The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stagesⅠ-Ⅱ. Int J Oncol, 2016, 48(3): 998-1006.
22.	Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer, 2011, 2(12): 1097-1105.
23.	劉景磊, 秦凈, 侯英勇, 等. 胃腸間質瘤患者血漿血管內皮生長因子的檢測及其臨床意義. 中華胃腸外科雜志, 2008, 11(6): 542-544.
24.	Basilio-de-Oliveira RP, Pannain VL. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol, 2015, 21(22): 6924-6930.

1. 中國臨床腫瘤學會胃腸間質瘤專家委員會. 中國胃腸間質瘤診斷治療共識(2017年版). 腫瘤綜合治療電子雜志, 2018, 4(1): 31-43.
2. Huang H, Liu YX, Zhan ZL, et al. Different sites and prognoses of gastrointestinal stromal tumors of the stomach: report of 187 cases. World J Surg, 2010, 34(7): 1523-1533.
3. Muranushi R, Hoshino K, Hagiwara K, et al. Hepatic pleomorphic leiomyosarcoma after surgery for gastric gastrointestinal stromal tumor: a case report. Surg Case Rep, 2019, 5(1): 62.
4. Costache MI, Ioana M, Iordache S, et al. VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Rom J Intern Med, 2015, 53(3): 199-208.
5. 楊顯金, 陳佳慧, 杜江, 等. 胃腸道間質瘤的診治現狀與進展. 中國普外基礎與臨床雜志, 2014, 21(8): 1040-1045.
6. Yang J, Gu Y, Huang X, et al. Prognostic impact of preoperative neutrophil-lymphocyte ratio for surgically resected gastrointestinal stromal tumors. Medicine (Baltimore), 2019, 98(16): e15319.
7. Parab TM, DeRogatis MJ, Boaz AM, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol, 2019, 10(1): 144-154.
8. 岳欣, 胡均, 王家倉. 甲磺酸伊馬替尼治療手術無法切除的晚期胃腸間質瘤. 中國腫瘤臨床, 2016, 43(23): 1049-1052.
9. Feng Y, Wang X, Wang Q. Expression of SATB1 and E-cad in tissues of patients with endometrial carcinoma and the relationship with clinicopathological features. Exp Ther Med, 2018, 15(5): 4339-4343.
10. Villagrasa P, Díaz VM, Vi?as-Castells R, et al. Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene, 2012, 31(36): 4022-4033.
11. 金鑫, 李靖, 錢軍. ALDH1、CXCR4、E-cadherin在胃癌組織中的表達及與淋巴結轉移的關系. 南方醫科大學學報, 2016, 36(10): 1390-1395.
12. 楊學民, 李朝路, 李兆陽. ICAM-1、MMP-9及E-cadherin在結直腸癌中的表達及意義. 癌癥進展, 2018, 16(10): 1284-1287.
13. K?vecsi A, Gurzu S, Szentirmay Z, et al. Paradoxical expression pattern of the epithelial mesenchymal transition-related biomarkers CD44, SLUG, N-cadherin and VSIG1/Glycoprotein A34 in gastrointestinal stromal tumors. World J Gastrointest Oncol, 2017, 9(11): 436-443.
14. Lim SC, Jang IG, Kim YC, et al. The role of E-cadherin expression in non-small cell lung cancer. J Korean Med Sci, 2000, 15(5): 501-506.
15. Kim NG, Koh E, Chen X, et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A, 2011, 108(29): 11930-11935.
16. 梁建芳, 鄭繪霞, 李寧, 等. 胃腸道間質瘤中P16基因甲基化和P16蛋白表達的臨床意義. 中華胃腸外科雜志, 2007, 10(4): 372-375.
17. Ravegnini G, Nannini M, Zenesini C, et al. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, 20(1): 139-148.
18. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
19. Hu F, Li H, Liu L, et al. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling. Mol Cancer, 2018, 17(1): 107.
20. Banys-Paluchowski M, Witzel I, Aktas B, et al. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Sci Rep, 2019, 9(1): 2318.
21. Skirnisdottir I, Seidal T, ?kerud H. The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stagesⅠ-Ⅱ. Int J Oncol, 2016, 48(3): 998-1006.
22. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer, 2011, 2(12): 1097-1105.
23. 劉景磊, 秦凈, 侯英勇, 等. 胃腸間質瘤患者血漿血管內皮生長因子的檢測及其臨床意義. 中華胃腸外科雜志, 2008, 11(6): 542-544.
24. Basilio-de-Oliveira RP, Pannain VL. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol, 2015, 21(22): 6924-6930.

Previous Article
Which T1 lung cancers require "radical therapy"?
Next Article
Research progress on Williams syndrome complicated with cardiovascular disease

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions of E-cadherin and vascular endothelial growth factor in gastrointestinal stromal tumors and their clinical significances

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content